Table 2.
Teleconsent
| ITEM | n | % |
|---|---|---|
| Teleconsent is an IMPORTANT APPROACH for obtaining informed consent | ||
| Strongly agree | 61 | 45.5 |
| Agree | 58 | 43.3 |
| Neither agree nor disagree | 14 | 10.5 |
| Disagree | 1 | 0.8 |
| Strongly disagree | 0 | 0.0 |
| I or my organization would LIKELY USE TELECONSENT to obtain informed consent if it were available | ||
| Strongly agree | 52 | 38.8 |
| Agree | 59 | 44.0 |
| Neither agree nor disagree | 21 | 15.7 |
| Disagree | 1 | 0.8 |
| Strongly disagree | 1 | 0.8 |
| The GREATEST OPPORTUNITIES for teleconsent to impact informed consent in clinical research include the following: | ||
| Consenting participants at their homes | 108 | 80.6 |
| Consenting participants at remote clinic sites | 116 | 86.6 |
| Increasing access to participants to clinical trials | 114 | 85.1 |
| Streamlining recruitment and consent process | 79 | 60.0 |
| Improving the efficiency of research staff | 74 | 55.2 |
| Greater confidentiality and privacy | 31 | 23.1 |
| Reduce regulatory burden on research staff at remote sites | 47 | 35.1 |
| Ability to confirm the person completing consent remote is actually that person | 59 | 44.0 |
| Ability to watch for nonverbal cues indicating comprehension or confusion | 68 | 50.8 |
| The GREATEST CHALLENGES with using teleconsent for informed consent in clinical research include the following: | ||
| Technical capabilities of users | 114 | 85.1 |
| Hardware availability of users | 97 | 72.4 |
| Internet connectivity | 93 | 69.4 |
| Privacy and confidentiality concerns | 52 | 38.8 |
| IRB and regulatory issues | 49 | 36.6 |